Anavex welcomes three new members to its scientific advisory board

Anavex Life Sciences has announced the appointment of three distinguished researchers to its …

Anavex reports net loss for fiscal year 2015 $12.1M

Anavex had cash and cash equivalents of $15.3 million as of September 30, 2015, compared with $7.3 million as at September 30, 2014. During fiscal year 2015 Anavex used $4.2 million in cash to fund operations. The net loss for fiscal year 2015 was $12.1 million or $0.65 per share compared to a net loss…

Anavex appoints Preclinical Operations vice president

Anavex has appointed Ulrich Elben, PhD as Vice President of Preclinical Operations, who will be responsible for the pipeline development and optimization.

Anavex promotes a vice president regulatory affairs

Kristina M. Capiak, CCRP has been promoted the Anavex Life Sciences Corp’s Vice President of Regulatory Affairs. She is overseeing U.S. and international regulatory matters for Anavex, including filings and interactions with the FDA and other regulatory authorities.

Anavex prepares for regulatory filings based on FDA guidance

Anavex is moving forward with the development program for ANAVEX 2-73 for the treatment of Alzheimer’s disease in a…

Anavex confirms positive efficacy Phase2 Alzheimer’s trial for its Anavex 2-73 datahad

Anavex has confirmed the information about positive safety and cognitive efficacy data from the Phase 2a Alzheimer’s trial for ANAVEX 2-73.

Anavex joins NASDAQ

Anavex Life Sciences Corp., has announced it would be trading its common stock on the NASDAQ, an American/Canadian stock exchange, one of the world’s largest. A clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer on Monday announced receiving approval to begin trading its common…